Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kappos, L.
Right arrow Articles by Duda, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kappos, L.
Right arrow Articles by Duda, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 125, No. 11, 2379-2380, November 2002
© 2002 Oxford University Press

Editorial

The Janus face of CNS-directed autoimmune response: a therapeutic challenge

Ludwig Kappos and Petra Duda

Departments of Neurology and Research, University Hospitals, Kantonsspital, Basel, Switzerland

The first 10% of the full text of this article appears below.

During the past two decades, much interest has focused on the pathogenic role of autoreactive T-cells recognizing myelin in both multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE). The vast majority of data support the hypothesis that EAE and, by analogy, multiple sclerosis are diseases mediated by autoreactive Th1 T-cells, much as rheumatoid arthritis, autoimmune diabetes, psoriasis or inflammatory bowel disease. Thus, much effort has been put into developing multiple sclerosis therapies that eliminate more or less specifically autoimmune T-cells or shift the balance from . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
U. Held, L. Heigenhauser, C. Shang, L. Kappos, C. Polman, and for the Sylvia Lawry Centre for MS Research
Predictors of relapse rate in MS clinical trials
Neurology, December 13, 2005; 65(11): 1769 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
O. Khan, Y. Shen, C. Caon, F e. Bao, W. Ching, M. Reznar, A. Buccheister, J. Hu, Z. Latif, A. Tselis, et al.
Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
Multiple Sclerosis, December 1, 2005; 11(6): 646 - 651.
[Abstract] [PDF]